• James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)
Recent Posts
  • James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)
  • Groupon Inc. (NASDAQ:GRPN) Rises With Increasing Revenues
  • Coca Cola Co. (NYSE:KO) To Fight Obesity – PEP
  • Christie Raises $6.2 Million For Reelection Bid
  • UnitedHealth Group Inc (NYSE:UNH) faces flak from Pentagon
  • Goldman Sachs Group, Inc (NYSE:GS) $31 million tax evasion under scrutiny – GOOG, SBUX

Business

Novartis AG (ADR) (NYSE:NVS) lost India

April 1, 2013 by Dan Young in Business, Technology with 0 Comments

Northern, WI 01/04/2013 (tradewatchmedia) – It has been confirmed that the Novartis AG (ADR) (NYSE:NVS) had lost the Indian patent case. The supreme court of India rejected application for the cancer drug Glivec. This has led to the Ex-Novartis chief Daniel Vasella to get back to US, which is the home for some of the world’s largest pharmaceuticals companies. He on 23 January announced that he would better leave the Swiss group after the annual general meeting of the company in February and this following week he also unregistered with some local authorities in the Risch, the municipality in the Zug’s canton.

Now he is fully determined to switch his residence from there where he was living for just last 10 years to the US. Under some of the terms of an agreement which marked his exit who led the company for last 17 years would receive an amount of 76 million dollars if he did not work for any of the other rivals of the Novartis AG (ADR) (NYSE:NVS). However the news leaked off last month and due to this MrVasella has left the agreement which means that now he is no more under the term that he will not work with anybody else. He even completed an executive training course at the Harvard Business school and even joined the board of the American Novartis last year.

Even the GSK is gearing up so as to expand the sales of flu jabs in the US. It has also applied to the government so as to grant permission for a new manufacturing plant as also the approval for a type of a vaccine ingredient. The Us food and drug administration has also issued a so called complete response letter so as to grant the permission to the GSk for its request of the authorization. And the company is now very much thankful to the US government.

Tagged ,

About Dan Young

Dan Young is a multimedia journalist who writes and edits articles, tweets regularly, posts blog items, shoots video and takes photos. Dan has appeared on Good Morning America, the Today show, CNN and ESPN. Dan joined the Times Indices Media team as a general assignment editor in July 2010. Dan developed his skills and passion for journalism while attending the University of Southern California and interning at local news stations.

View all posts by Dan Young →

Related Posts

Leave a reply

Your email address will not be published. Required fields are marked *

*

Trade Watch Media Company
Trade Watch Media Company 320 North Dearborn Street Chicago, IL

Contact Us / Phone Us

  • Support:312-744-1856
  • Media:312-744-1932
  • Sales:312-744-1933
Trending..
  • James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)